Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly shots aim to boost growth in kids with dwarfism

NCT ID NCT05929807

ENROLLING_BY_INVITATION Disease control Sponsor: Ascendis Pharma Growth Disorders A/S Source: ClinicalTrials.gov ↗

Summary

This study continues testing a weekly injection called TransCon CNP in children and teenagers with achondroplasia, a genetic condition that affects bone growth. It's for participants who have already completed an earlier trial with the same medication. The main goals are to check long-term safety and see if the treatment helps improve height growth until participants' bones stop growing naturally.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ascendis Investigational Site

    Aurora, Colorado, 80045, United States

  • Ascendis Investigational Site

    Wilmington, Delaware, 19803, United States

  • Ascendis Investigational Site

    Saint Paul, Minnesota, 55102, United States

  • Ascendis Investigational Site

    Houston, Texas, 77030, United States

  • Ascendis Investigational Site

    Linz, 4020, Austria

  • Ascendis Investigational Site

    Montreal, H3T 1C5, Canada

  • Ascendis Investigational Site

    Berlin, 13353, Germany

  • Ascendis Investigational Site

    Auckland, 1023, New Zealand

  • Ascendis Investigational Site

    Coimbra, 3000-602, Portugal

  • Ascendis Investigational Site

    Vitoria-Gasteiz, 1008, Spain

  • Ascendis Pharma Investigational Site

    Little Rock, Arkansas, 72202, United States

  • Ascendis Pharma Investigational Site

    Columbia Falls, Montana, 65212, United States

  • Ascendis Pharma Investigational Site

    Buffalo, New York, 14203, United States

  • Ascendis Pharma Investigational Site

    Madison, Wisconsin, 53705, United States

  • Ascendis Pharma Investigational Site

    Parkville, Victoria, 3052, Australia

  • Ascendis Pharma Investigational Site

    Copenhagen, 2100, Denmark

  • Ascendis Pharma Investigational Site

    Dublin, D01 YC76, Ireland

Conditions

Explore the condition pages connected to this study.

ACHONDROPLASIA